MOLECULAR FINGERPRINTING METHODS TO DETECT AND GENOTYPE DNA TARGETS THROUGH POLYMERASE CHAIN REACTION

Abstract

A molecular fingerprinting method is disclosed to detect and genotype pathogens DNA targets in a sample through polymerase chain reaction (PCR). The method comprises performing PCR amplification and then a High Resolution Melting (HRM) analysis. The PCR reaction mixture used comprises two or more pairs of amplification primers designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in the HRM analysis, each amplicon by observing the specific melting temperature of each amplicon. The method further comprises monitoring, during the HRM analysis, the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons into two single-stranded DNAs, due to the release of the intercalating molecule or compound. Discrimination and genotyping of different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in the sample can be determined through a reader analysing the signal variation; the result of the analysis is obtained through a graphic interface connected to the reader.

Claims

1. A molecular fingerprinting method to detect and genotype pathogens DNA targets in a sample through polymerase chain reaction (PCR), said method being able to discriminate and genotype different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations, said method comprising: providing a PCR reaction mixture comprising an amplification buffer comprising an intercalating molecule or compound incorporated into the double-stranded amplicon and emitting a detectable signal; performing PCR amplification using said PCR reaction mixture and said sample; performing, at the end of the PCR amplification, a High Resolution Melting (HRM) analysis on the PCR reaction mixture and the sample previously subjected to PCR amplification; wherein the PCR reaction mixture comprises two or more pairs of amplification primers for amplifying in a multiplex approach two or more target nucleic acids, wherein said amplification primers are designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in the HRM analysis, each amplicon by observing the specific melting temperature of each amplicon, wherein the method further comprises monitoring, during the HRM analysis, the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons into two single-stranded DNAs, due to the release of the intercalating molecule or compound, wherein the method further comprises determining discrimination and genotyping of different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in the sample, through a reader analysing the signal variation and obtaining the result of the analysis through a graphic interface connected to said reader.

2. The method according to claim 1, wherein said amplification primers are designed to amplify pathogen DNA targets producing corresponding amplicons, each from 38 to 1500 bps.

3. The method according to claim 1 or 2, wherein the amplification primers are designed to amplify an amplicon, wherein the melting peak of the amplicon is between 68 and 95 C.

4. The method according to claim 1, 2 or 3, wherein each amplification primer is present in the PCR reaction mixture at a final concentration range from 50 to 1000 nanomolar (nM).

5. The method according to any of claims 1 to 4, wherein the amplification buffer of the PCR reaction mixture further comprises a DNA polymerase, deoxynucleoside triphosphates (dNTPs) or analogues, a buffer solution, water, a source of monovalent or bivalent cations, bovine serum albumin (BSA).

6. The method according to claim 5, wherein the amplification buffer of the PCR reaction mixture further comprises additives selected between one, more or all of additives in a group comprising: NP40, DMSO, TMAC (Tetramethylammonium Cloride), Acetamide, Triton, Formamide, Betaine, E. coli ssDNA binding protein, Glycerol, L-Carnitine and Gelatine.

7. The method according to any of claims 1 to 6, wherein performing PCR amplification using said PCR reaction mixture includes amplifying the target purified nucleic acid using said PCR reaction mixture to generate an amplicon, wherein amplifying the target purified nucleic acid includes thermocycling by repeatedly performing a ramp of temperature, wherein, during thermocycling in the PCR amplification, monitoring the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons or amplification products into two single-stranded DNAs, due to the release of the intercalating molecule or compound, is performed, wherein said ramp of temperature comprises performing the following temperature steps: denaturation at 95-98 C. from 1 to 30 seconds; annealing in a range between 50 C. and 70 C. from 1 to 60 seconds; extension in a range between 60 C. and 75 C. from 0 second to 5 minutes.

8. The method according to any of claims 1 to 7, wherein performing HRM analysis includes performing a ramp of temperature for HRM on the PCR reaction mixture previously subjected to PCR amplification and, during the ramp of temperature, performing said monitoring the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons into two single-stranded DNA, due to the release of the intercalating molecule or compound, wherein said ramp of temperature comprises includes performing the following temperature steps: incubation at 95 C. from 1 seconds to 60 seconds incubation at 60 C. from 30 seconds to 2 minutes ramping up to 95 C. increasing the temperature 0.1 C./second or less.

9. The method according to any of claims 1 to 8, wherein the PCR amplification occurs in a real-time PCR machine or in a thermocycling machine able to acquire said signal emission each 0.1 C./second or less.

10. The method according to any of claims 1 to 9, wherein in case a formation of primer dimers causes aspecific fluorescent background, one or more of said amplification primers are stem-loop hybrid primers designed to reduce the formation of primer dimers, each said stem-loop hybrid primers comprising a priming portion, a loop portion, a competitive palindromic portion and a 5 fidelity tail, wherein said priming portion is a sequence that is complementary to the target sequence and ranges from 15 to 60 bps, wherein said loop portion contains from 30% to 90% of the priming portion bases and forms a stable and unique hairpin structure, juxtaposed to the 5 of the priming portion, the loop portion containing a DNA polymerase stopping site, modulated by the presence of at least one 1,2-Dideoxyribose, an equivalent abasic nucleotide, preceded or followed by at least one 1,2-Dideoxyribose, or at least one polyethylen glycol. are suitable, but the preferential molecule is triethylene glycol (TEG), wherein said competitive palindromic portion is complementary to the priming portion, it is at least one nucleotide shorter than the priming sequence and it contains a DNA polymerase stopping site composed as the DNA polymerase stopping site of the loop portion, wherein said 5 fidelity tail length ranges from 1 to 1000 nucleotides, it contains bases or bases analogues and is complementary or partially complementary to the downstream region of the target sequence.

11. The method according to any of claims 1 to 10, wherein said PCR amplification is performed in a thermocycler or in a real-time PCR thermocycler, wherein, when the PCR amplification is performed in a thermocycler, HRM analysis is performed in a separate instrument, while when the PCR amplification is performed in a real-time PCR thermocycler, HRM analysis is performed in the same real-time PCR thermocycler.

12. The method according to any of claims 1 to 11, wherein said PCR reaction mixture is loaded periodically with a melting temperature calibrator to check the effective melting temperature of the amplicons of a particular thermocycler machine, and compare it with an expected melting temperature, wherein said calibrator is composed by synthetic oligonucleotides corresponding to the amplicons generated by the specific primers of the PCR reaction mixture.

13. The method according to any of claims 1 to 12, wherein two or more sets of primers are further used that are specific for the same DNA targets, wherein a first set is present in a PCR reaction mixture in one well, at least a second set is present in another well, wherein each set of primers comprises primers each recognizing one specific DNA target, wherein the DNA targets recognized by the first set of primers are the same as the DNA targets recognized by the second set of primers, wherein the melting temperature of an amplicon generated by a primer of one set of primers recognizing a specific DNA target is different from the melting temperature of an amplicon generated by a primer of the other set of primers recognizing said specific DNA target, wherein, for each target DNA, HRM data are collected for each well, such that each target DNA is defined for several melting peaks, one for each well.

14. The method according to any of claims 1 to 13, wherein in case a formation of primer dimers causes aspecific fluorescent background, said PCR reaction mixture further comprises decoy oligonucleotides ranging from 10 to 100 nucleotides and complementary for at least 50% to said specific amplification primers, wherein the difference between the melting temperature of each decoy oligonucleotide and the relative paired primer does not exceed 2 C.

15. The method according to any of claims 1 to 14, wherein the pathogen is a pathogen responsible for a sexually transmitted disease or infection.

16. The method according to claim 15, wherein the pathogen is human papilloma virus (HPV).

17. The method according to claim 16, wherein said amplification primers include one or more specific primers for each genotype of HPV.

18. The method according to claim 17, wherein said specific primers for each genotype of HPV generate amplicons that have difference in melting temperature not exceeding 30 C.

19. The method according to claim 16, 17 or 18, wherein said amplification primers include one or more of the following specific primers for each genotype of HPV: from SEQ ID No. 20 to SEQ ID No. 616 and from SEQ ID No. 655 to SEQ ID No.706.

20. The method according to claim 15, wherein the pathogen is a pathogen selected in a group consisting of the pathogens responsible for: chlamydia infection, syphilis infection, or gonorrhoea infection.

21. The method according to claim 20, wherein said amplification primers include one or more of the following specific primers: SEQ ID No. 1 to SEQ ID No. 19 and from SEQ ID No. 636 to SEQ ID No. 654, for genotype of respectively said chlamydia infection, syphilis infection, gonorrhoea infection.

22. The method according to any of claims 1 to 21, wherein one further set of normalizing primers are further used, said amplification of human genomic DNA serving as an internal PCR validation control and/or control for normalization of the amplified pathogen DNA obtained.

23. The method according to claim 22, wherein said pathogen is HPV and a pair of said normalizing primers targets a fragment from the human beta-globin gene and is provided in SEQ ID No. 617 to SEQ ID No. 629.

24. A diagnostic kit to detect and genotype DNA targets, said kit comprising a Polymerase Chain Reaction (PCR) reaction mixture used for performing PCR amplification and a subsequent a High Resolution Melting (HRM) analysis on the PCR reaction mixture previously subjected to real-time PCR, wherein said PCR reaction mixture comprises two or more pairs of amplification primers for amplifying in a multiplex approach two or more target nucleic acids, wherein said primers are designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in the HRM analysis, each amplicon by observing the specific melting temperature of each amplicon.

25. The diagnostic kit according to claim 24, wherein said amplification primers are designed to amplify pathogen DNA targets producing corresponding amplicons, each from 40 to 1500 bps.

26. The diagnostic kit according to claim 24 or 25, wherein the amplification primers are designed to amplify an amplicon, wherein the melting peak of the amplicon is between 68 and 95 C.

27. The diagnostic kit according to claim 24, 25 or 26, wherein each amplification primer is present in the PCR reaction mixture at a final concentration range from 50 to 1000 nanomolar (nM).

28. The diagnostic kit according to any of claims 25 to 27, wherein said PCR reaction mixture comprises an amplification buffer comprising a DNA polymerase, deoxynucleoside triphosphates (dNTPs) or analogues, a buffer solution, water, a source of monovalent or bivalent cations, bovine serum albumin (BSA).

29. The diagnostic kit according to claim 28, wherein said amplification buffer further comprises additives selected between one, more or all of additives in a group comprising: NP40, DMSO, TMAC (Tetramethylammonium Cloride), Acetamide, Triton, Formamide, Betaine, E. coli ssDNA binding protein, Glycerol, L-Carnitine and Gelatine.

30. The diagnostic kit according to any of claims 24 to 29, wherein in case a formation of primer dimers causes aspecific fluorescent background, one or more of said amplification primers are stem-loop hybrid primers designed to reduce the formation of primer dimers, each said stem-loop hybrid primers comprising a priming portion, a loop portion, a competitive palindromic portion and 5 fidelity tail, wherein said priming portion is a sequence that is complementary to the target sequence and ranges from 15 to 60 bps, wherein said loop portion contains from 30% to 90% of the priming portion bases and forms a stable and unique hairpin structure, juxtaposed to the 5 of the priming portion, the loop portion containing a DNA polymerase stopping site, modulated by the presence of at least one 1,2-Dideoxyribose, an equivalent abasic nucleotide, preceded or followed by at least one 1,2-Dideoxyribose or at least one polyethylen glycol. are suitable, but the preferential molecule is triethylene glycol (TEG), wherein said competitive palindromic portion is complementary to the priming portion, it is at least one nucleotide shorter than the priming sequence and it contains a DNA polymerase stopping site composed as the DNA polymerase stopping site of the loop portion, wherein said 5 fidelity tail length ranges from 1 to 1000 nucleotides, it contains bases or bases analogues and is complementary or partially complementary to the downstream region of the target sequence.

31. The diagnostic kit according to any of claims 24 to 30, wherein in case a formation of primer dimers causes aspecific fluorescent background, said PCR reaction mixture further comprises decoy oligonucleotides ranging from 10 to 100 nucleotides and complementary for at least 50% to said specific amplification primers, wherein the difference between the melting temperature of each decoy oligonucleotide and the relative paired primer does not exceed 2 C.

32. The diagnostic kit according to any of claims 24 to 31, wherein the pathogen is a pathogen responsible for a sexually transmitted disease or infection.

33. The diagnostic kit according to claim 32, wherein the pathogen is human papilloma virus (HPV).

34. The diagnostic kit according to claim 33, wherein said amplification primers include one or more specific primers for each genotype of HPV.

35. The diagnostic kit according to claim 34, wherein said specific primers for each genotype of HPV generate amplicons that have difference in melting temperature not exceeding 30 C.

36. The diagnostic kit according to claim 33, 34 or 35, wherein said amplification primers include one or more of the following specific primers for each genotype of HPV: from SEQ ID No. 20 to SEQ ID No. 616 and from SEQ ID No. 655 to SEQ ID No.706.

37. The diagnostic kit according to claim 32, wherein the pathogen is a pathogen selected in a group consisting of the pathogens responsible for: chlamydia infection, syphilis infection, or gonorrhoea infection.

38. The diagnostic kit according to claim 37, wherein said amplification primers include one or more of the following specific primers: SEQ ID No. 1 to SEQ ID No. 19 and from SEQ ID No. 636 to SEQ ID No. 654, for genotype of respectively said chlamydia infection, syphilis infection, gonorrhoea infection.

39. Amplification primers for performing a molecular fingerprinting method to detect and genotype pathogens DNA targets through Polymerase Chain Reaction (PCR), wherein the method is able to discriminate and genotype different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in a single reaction, wherein said amplification primers are provided for amplifying in a multiplex approach two or more target nucleic acids in a PCR amplification, wherein said primers are designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in a High Resolution Melting (HRM) analysis following the PCR amplification, each amplicon by observing the specific melting temperature of each amplicon.

40. The amplification primers according to claim 39, wherein the pathogen is a pathogen responsible for a sexually transmitted disease or infection.

41. The amplification primers according to claim 40, wherein the pathogen is human papilloma virus (HPV).

42. The amplification primers according to claim 41, wherein said amplification primers include one or more specific primers for each genotype of HPV.

43. The amplification primers according to claim 42, wherein said specific primers for each genotype of HPV generate amplicons that have difference in melting temperature not exceeding 30 C.

44. The amplification primers according to claim 41, 42 or 43, wherein said amplification primers include one or more of the following specific primers for each genotype of HPV: from SEQ ID No. 20 to SEQ ID No. 616 and from SEQ ID No. 655 to SEQ ID No. 706.

45. The amplification primers according to claim 41, wherein the pathogen is a pathogen selected in a group consisting of the pathogens responsible for: chlamydia infection, syphilis infection, or gonorrhoea infection.

46. The amplification primers according to claim 45, wherein said amplification primers include one or more of the following specific primers: SEQ ID No. 1 to SEQ ID No. 19 and from SEQ ID No. 636 to SEQ ID No. 654, for genotype of respectively said chlamydia infection, syphilis infection, gonorrhoea infection.

47. An apparatus for performing a molecular fingerprinting method to detect and genotype pathogens DNA targets through Polymerase Chain Reaction (PCR) is provided, wherein said method is able to discriminate and genotype different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in a single reaction, wherein said apparatus comprises: a PCR reaction mixture comprising an amplification buffer comprising an intercalating molecule or compound incorporated into the double-stranded amplicon and emitting a detectable signal; a PCR amplification device configured for using said PCR reaction mixture and said sample; a device for performing a HRM analysis on the PCR reaction mixture and the sample previously subjected to PCR amplification; wherein the PCR reaction mixture comprises two or more pairs of amplification primers for amplifying in a multiplex approach two or more target nucleic acids, wherein said primers are designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in the HRM analysis, each amplicon by observing the specific melting temperature of each amplicon; monitoring means for monitoring, during the HRM analysis, the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons into two single-stranded DNA, due to the release of the intercalating molecule or compound, a reader analysing the signal variation for determining discrimination and genotyping of different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in the sample, so that the result of the analysis can be obtained through a graphic interface connected to said reader.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0059] So that the manner in which the above recited features of the present invention can be understood in detail, a more particular description of the invention, briefly summarized above, may be had by reference to embodiments. The accompanying drawings relate to embodiments of the disclosure and are described in the following:

[0060] FIG. 1 is a graph showing the performance of the system presented in this invention with particular reference to the quality of melting curve. The black melting plot shows a better performance with a lower initial fluorescence background compared to melting curves obtained with standard PCR buffer (grey graph);

[0061] FIG. 2 is a graph showing Derivative Fluorescence vs. Temperature curves with specific primers designed to obtain different melting temperature for each HPV genotype, allowing simultaneous precise identification of the most common high risk genotypes;

[0062] FIG. 3 shows hybrid primers structures, in schematic and 3D-structures, with (A and B) and without (C and D) the 5 fidelity tail.

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0063] Reference will now be made in detail to the various embodiments of the invention, using the attached figures. Generally, only the differences with respect to individual embodiments are described. Each example is provided by way of explanation of the invention and is not meant as a limitation of the invention. For example, features illustrated or described as part of one embodiment can be used on or in conjunction with other embodiments to yield yet a further embodiment. It is intended that the present invention includes such modifications and variations.

[0064] Before describing these embodiments, it shall be also clarified that the present description is not limited in its application to details of the construction and disposition of the components as described in the following description using the attached drawings. The present description can provide other embodiments and can be obtained or executed in various other ways. It shall also be clarified that the phraseology and terminology used here is for the purposes of description only, and cannot be considered as limitative.

[0065] All the percentages and ratios indicated refer to the weight of the total composition (for example indicated as % w/w), unless otherwise indicated. All the measurements are made, unless otherwise indicated, at 25 C. and atmospheric pressure. All the temperatures, unless otherwise indicated, are expressed in degrees Centigrade.

[0066] All the ranges reported here shall be understood to include the extremes, including those that report an interval between two values. Furthermore, all the ranges reported here shall be understood to include and describe the punctual values included therein, and also all the sub-intervals. Moreover, all the ranges are intended as such that the sum of the values comprised therein, in the final composition, gives 100%, in particular considering that the person of skill will know how to choose the values of the ranges so that the sum does not exceed 100%.

[0067] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0068] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.

[0069] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, it will be readily apparent to one of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0070] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. To the extent such publications may set out definitions of a term that conflicts with the explicit or implicit definition of the present disclosure, the definition of the present disclosure controls. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0071] Embodiments of the present disclosure generally relate to molecular fingerprinting method to detect and characterize DNA targets in a sample through PCR is provided. The method of the present disclosure is able to discriminate and genotype different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in a single reaction. In one embodiment, the method includes: [0072] providing a PCR reaction mixture comprising an amplification buffer comprising an intercalating molecule or compound incorporated into the double-stranded amplicon and emitting a detectable signal; [0073] performing PCR amplification using said PCR reaction mixture and said sample; [0074] performing, at the end of the PCR amplification, a HRM analysis on said PCR reaction mixture and said sample previously subjected to PCR amplification; [0075] wherein the PCR reaction mixture comprises two or more pairs of amplification primers for amplifying in a multiplex approach two or more target nucleic acids, [0076] wherein said amplification primers are designed in order to generate amplicons with a different melting temperature each other in order to discriminate, in the HRM analysis, each amplicon by observing the specific melting temperature of each amplicon, [0077] wherein the method further comprises monitoring, during the HRM analysis, the change in the signal emission resulting from the temperature-induced denaturation of the double-stranded amplicons into two single-stranded DNA, due to the release of the intercalating molecule or compound, [0078] wherein the method further comprises determining discrimination and genotyping of different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations in the sample, through a reader analysing the signal variation and obtaining the result of the analysis through a graphic interface connected to said reader.

[0079] According to embodiments, combinable with all embodiments described herein, the DNA target that can be detected and genotyped is a pathogen DNA target.

[0080] Advantageously, using the embodiments described herein, it is possible to detect and discriminate: [0081] different types of a specific pathogen (e.g. the 14 different high risk HPV strains); [0082] different pathogens (e.g. different pathogens responsible for sexually transmitted diseases, such as HPV, syphilis infection, gonorrhoea infection, HIV); [0083] different alleles of a cell gene (e.g. different mutations of the human BRCA gene); [0084] different allele of several cell genes (e.g. different mutations of BRCA gene, of K-RAS gene or other genes).

[0085] Advantageously, the sample can be a crude sample. The crude sample can be vaginal or cervical mucus, other bodily fluids, saliva, blood, urine, biopsies, formalin-fixed paraffin-embedded (FFPE) tissue, cells, fine needle aspiration biopsies or similar. The crude sample can be diluted prior to performing the PCR amplification and HRM analysis.

[0086] According to possible embodiments, combinable with all embodiments described herein, the signal variation between an input and an output signal can be detected in a circuit comprised in the reader, wherein said variation is a function of the presence, amount, genotype of different strains of the same pathogen, different pathogens belonging to separated genus and genetic variations present in the sample.

[0087] According to embodiments, combinable with all embodiments described herein, performing PCR amplification using said PCR reaction mixture includes amplifying the target purified nucleic acid using said PCR reaction mixture to generate an amplicon or amplification product.

[0088] According to embodiments, combinable with all embodiments described herein, the amplification primers are sufficiently complementary to the target nucleic acid to hybridize therewith and trigger polymerase-mediated synthesis.

[0089] In one specific embodiment, combinable with all embodiments described herein, the amplification primers are designed to amplify specifically pathogen DNA targets (e.g. HPV genotypes) producing corresponding amplicons, each from 38 to 1500 base pairs (bps).

[0090] In one further specific embodiment, combinable with all embodiments described herein, the amplification primers are designed to amplify an amplicon wherein the melting peak of the amplicon is between 68 and 95 C.

[0091] In still another embodiment, combinable with all embodiments described herein, each amplification primer is present in the PCR reaction mixture at a final concentration range from 50 to 1000 nanomolar (nM).

[0092] According to embodiments, combinable with all embodiments described herein, the PCR reaction mixture comprises the amplification primers and the amplification buffer.

[0093] According to embodiments, the amplification buffer is comprised in a diagnostic kit that is part of the present disclosure.

[0094] In one embodiment, combinable with all embodiments described herein, besides the above mentioned two or more pairs of amplification primers, the PCR reaction mixture comprises a DNA polymerase. The DNA polymerase is comprised in said amplification buffer. The DNA polymerase is an enzyme that polymerizes new DNA strands. For instance, heat resistant or heat stable polymerase can be used, since it is more likely to remain intact during the high-temperature DNA denaturation process. One example of heat resistant or heat stable polymerase that can be used in embodiments described herein is taq polymerase. Moreover, the polymerase that can be used in association with embodiments described herein is a hot-start polymerase. In a possible implementation, the hot-start polymerase can be (Hot Start) @Taq DNA Euroclone, (Hot Start) Phire Thermo Scientific, (Hot Start) Phusion Thermo Scientific, or (Hot Start) Gold Taq polymerase Sigma.

[0095] In one further embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise deoxynucleoside triphosphates (dNTPs) or analogues. dNTPs or analogues are comprised in said amplification buffer. dNTPs or analogues are used to provide the building blocks from which the DNA polymerase synthetizes a new DNA strand. dNTPs can be substituted by functional analogues like adenine, cytosine, guanine, tymine, uracil, orotidine, inositate, xanthylate.

[0096] As above described, the PCR reaction mixture comprises said intercalating molecule or compound, being incorporated into the double-stranded amplicon or amplification product and emitting fluorescence or any other detectable signal. The intercalating molecule or compound can be comprised in said amplification buffer.

[0097] In particular, according to embodiments, the intercalating molecule can be any sensor or reporter molecule emitting a signal that can be detected by a reader analysing an electric signal variation in terms of inductance, current, electric potential, in case of conductimetric, amperometric, voltammetric detection, or the presence of light at specific wavelengths, in case of a fluorescence/chemiluminescence detection, or light scattering and/or refraction/diffraction phenomena, in case of a plasmonic optical detection.

[0098] For instance, in some implementations the intercalating molecule or compound can be an intercalating dye emitting fluorescence. According to possible implementations, specific DNA intercalating dye, at a final concentration range from 1 to 8 M, can be one or more of the following dyes: SYTO-9, SYTO-13, SYTO-16, SYTO-64, SYTO-82, YO-PRO-1, SYTO-60, SYTO-62, TOTO-3, POPO-3, BOBO-3, doxorubicin-conjugated quantum dot nanoparticles or similar.

[0099] In yet another embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise a buffer solution. The buffer solution is comprised in said amplification buffer. The buffer solution provides a suitable chemical environment for optimum activity and stability of DNA polymerase. For instance, the buffer solution may comprise water, in particular deionized water, TrisHCl and/or KCl and possibly in some cases MgCl.sub.2.

[0100] In one embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise a pH stabilizer.

[0101] In one further embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise preservatives.

[0102] In still another embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise water.

[0103] In yet another embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise a source of monovalent or bivalent cations. The source of monovalent or bivalent cations is comprised in said amplification buffer. For example, a chloride containing monovalent ion or bivalent ions can be used. As a source of monovalent cations, potassium ions can be used. K.sup.+ can be obtained from potassium salts, e.g. potassium chloride, in particular potassium chloride at a concentration of about 0.1 M. As source of bivalent cations magnesium or manganese ions can be used. Mg.sup.2+ can be obtained from magnesium salts, e.g. magnesium chloride.

[0104] In one further embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise bovine serum albumin (BSA). The BSA is comprised in said amplification buffer.

[0105] In one further embodiment, combinable with all embodiments described herein, the PCR reaction mixture further comprises one or more detergents. In possible implementations, said detergent can be Nonidet-P40 at a concentration of about 0.5%.

[0106] In still another embodiment, combinable with all embodiments described herein, the PCR reaction mixture may further comprise additives. The additives can be comprised in some embodiments of the above-mentioned amplification buffer. In possible implementations, the additives that can be used are selected among one, more or all of additives in a group comprising: NP40, DMSO, TMAC (Tetramethylammonium Cloride), Acetamide, Triton, Formamide, Betaine, E. coli ssDNA binding protein, Glycerol, L-Carnitine and Gelatine. Advantageously, in embodiments exploiting a fluorescence detection, the presence of additives can be important to avoid a high basal fluorescence background allowing an increased diagnostic sensitivity, specificity and accuracy (see FIG. 1). In some possible implementations, the additives may further comprise a gelatin, for example at a concentration of about 0.1%. In yet further possible implementations, the additives may further comprise an enhancer. For example, the enhancer can be L-Carnitin at a concentration of about 0.42M. In still further possible implementations, the additives may further comprise sugar alcohol, for example sorbitol at a concentration of about 25 mM.

[0107] According to embodiments, combinable with all embodiments described herein, amplifying the target purified nucleic acid using said PCR reaction mixture, to generate an amplicon or amplification product, includes thermocycling by performing a ramp of temperature steps. In one possible implementation, a ramp of temperature includes performing the following temperature steps: [0108] denaturation at 95-98 C. from 1 to 30 seconds; [0109] annealing in a range between 50 C. and 70 C. from 1 to 60 seconds; [0110] extension in a range between 60 C. and 75 C. from 0 second to 5 minutes.

[0111] In possible implementations, the number of cycles of thermocycling is of at least 30 cycles, for instance between 30 and 50 cycles. One possible example is 35 cycles.

[0112] In one possible implementation, hot-start polymerase can be used. Hot-start PCR avoids a non-specific amplification of DNA by inactivating the polymerase at lower temperatures, for instance through antibodies interaction, chemical modification or aptamer technology. Typically, a specific inhibitor, such as an aptamer-based inhibitor or specific antibodies can be used to block the polymerase at lower temperatures. If hot-start polymerase is used, an initial incubation step which ranges from 95 C. to 98 C. for 1 second to 10 minutes is performed. This initial incubation step is necessary for activation of polymerase.

[0113] According to embodiments, combinable with all embodiments described herein, the method includes, during thermocycling in the PCR amplification, performing the monitoring emission signal changing, e.g. fluorescence, resulting from the temperature-induced denaturation of the double-stranded amplicons or amplification products into two single-stranded DNA, due to the releasing of the intercalating molecule or compound, i.e. intercalating dye. The intercalating molecule or compound binds to DNA in the double-strand configuration. At each amplification cycle, amplicons are generated in which the intercalating molecule or compound binds in the extension step, during which the signal (e.g. fluorescence) is acquired.

[0114] Advantageously, the PCR reaction can occur in a real-time PCR machine, that allows monitoring the change in the signal, e.g. fluorescence, emission at each amplification cycle in the PCR amplification, in turn allowing quantification of the presence of amplicons and quantification, therefore, of the viral DNA in the amplification phase.

[0115] In other embodiments, the PCR amplification may occur in a thermocycling machine able to acquire said signal emission each 0.1 C./second or less.

[0116] According to embodiments, combinable with all embodiments described herein, the HRM analysis includes performing a ramp of temperature on the PCR reaction mixture previously subjected to PCR amplification. In one possible implementation, a ramp of temperature includes performing the following temperature steps: [0117] incubation at 95 C. from 1 seconds to 60 seconds [0118] incubation at 60 C. from 1 seconds to 2 minutes [0119] ramping up to 95 C. increasing the temperature 0.1 C./second or less, and performing said monitoring the change in the signal, e.g. fluorescence, emission resulting from the temperature-induced denaturation of the double-stranded amplicons or amplification products into two single-stranded DNA, due to the release of the intercalating molecule or compound, i.e. intercalating dye.

[0120] Advantageously, monitoring the change in the signal, e.g. fluorescence, emission in the HRM analysis, during which the large quantity of viral amplicons generated after the plurality of amplification thermocycling, allows to analyse the melting features of such amplicons at different temperatures. At low temperature, e.g. 60 C., amplicons are all double-stranded and the maximum level of signal, e.g. fluorescence, is detected. By slowly increasing temperature, however, amplicons start to denaturate up to complete separation into two single-stranded DNA and at this point the signal, e.g. fluorescence, will not be generated anymore. For instance, the shape and development of the Derivative Fluorescence vs. Temperature curves, as shown in FIG. 2, that can be generated by the above-mentioned monitoring, change depending on the sequence. The present disclosure exploits this feature to discriminate the viral genotype, because the primes used are designed such as to generate amplicons with a specific and different melting temperature each. In other words, the amplification primers designed according to the present disclosure allow to amplify amplicons with a precise and specific melting temperature fingerprint each.

[0121] Therefore, according to advantageous embodiments using a real-time PCR machine, after monitoring the change in in the signal, e.g. fluorescence, emission at each amplification cycle in the real-time PCR, it will be possible to know if the analysed sample is infected or not by a pathogen or a group of pathogens, e.g. a virus, and also by which one of the possible genotypes that can be detected.

[0122] Moreover, according to the present disclosure, after monitoring the change in in the signal, e.g. fluorescence, emission in the HRM analysis it will be possible to know, in the case that a sample is infected, also exactly the specific genotype or strain of the pathogen infecting the sample, or which exact pathogen of the group of pathogens.

[0123] The overall result is therefore that it will be possible, in advantageous embodiments using the real-time PCR, to know, via the real-time PCR, if a patient if positive or not to a specific pathogen, or a group of pathogens and, when positive, to know, via HRM analysis, the genotype or strain of pathogen that is infecting the patient or to know the specific pathogen from the detected group of pathogens.

[0124] In still further embodiments described using FIG. 3, which are combinable with all embodiments described herein, in case a formation of primer dimers causes aspecific fluorescent background, one or more of the above-mentioned amplification primers are specific stem-loop hybrid primers designed to reduce the formation of primer dimers. These specific stem-loop hybrid primers are therefore specific variants of the amplification primers described above and used in the PCR reaction mixture. Advantageously, said particular stem-loop hybrid primers are included in amplification reaction to avoid primer dimers and aspecific primer interactions with off target template sequences. These stem-loop hybrid primers enable to design amplicons with a very specific predicted melting temperature, facilitating the amplicon temperature melting-dependent design, due to their chemical composition that impedes both the DNA polymerase adding supplementary DNA bases and primer heterodimer formation. These stem-loop hybrid primers are DNA oligonucleotides that differ from standard primers in terms of structure and chemical composition.

[0125] The stem-loop hybrid primers according to embodiments described herein act through two distinct mechanisms: a competitive mechanism that protects the primer from both aspecific interactions and self-interaction; and a DNA polymerase stop-system that allows to generate only the desired amplicon with the predicted melting features. The oligonucleotides of the stem-loop hybrid primers are structured in 4 domains: 1) a priming portion, 2) a loop portion, 3) a competitive palindromic portion and 4) a 5 fidelity tail (see FIG. 3).

[0126] According to embodiments, the priming portion 1) is a sequence present in the actual primer sequence that is complementary to the target sequence and it may range from 15 to 60 bases. The target sequence is a DNA sequence present in the pathogen genome that has at least 50% of identity with the priming portion.

[0127] According to embodiments, the loop portion 2) can contain from 30% to 90% of the priming portion bases and it forms a stable and unique hairpin structure. The loop portion contains a number of nucleotides (adenine, cytosine, timine, guanine, uracil, orotidine, inosinate, xanthylate) or DNA base analogue, in order to form a stable loop structure. Juxtaposed to the 5 of the priming portion, the sequence of the loop portion contains a DNA polymerase stopping site (processivity blocker). This stopping site can be modulated by the presence of at least one 1,2-Dideoxyribose, or an equivalent abasic nucleotide, preceded or followed by at least one 1,2-Dideoxyribose or at least one polyethylen glycol. The stopping site can be formed even by only PEG (polyethylene glycol) molecules in a structure which has the space-filling of at least 2 nucleotides. In this embodiment, several members of PEG family are suitable, but the preferential molecule is triethylene glycol (TEG).

[0128] According to embodiments, the competitive palindromic portion 3) is complementary to the sequence of the priming portion. The competitive palindromic portion is at least one nucleotide shorter than the priming sequence. The 5 end of the competitive palindromic portion contains a DNA polymerase stopping site (processivity blocker) composed as described above with reference to the loop portion 2).

[0129] According to embodiments, the 5 fidelity tail length ranges from 1 to 1000 nucleotides, it contains bases or bases analogues (adenine, cytosine, timine, guanine, uracil, orotidine, inosinate, xanthylate) and is complementary or partially complementary to the downstream region of the target sequence.

[0130] In still further embodiments, in case a formation of primer dimers causes aspecific fluorescent background, decoy oligonucleotides can be employed in the PCR reaction mixture as above-described, in order to decrease the aspecific signal due to primer-dimer formations. Decoy oligonucleotides generally are oligonucleotide fragments able to bind to and block transcription and respectively translation factors. In these embodiments, decoy oligonucleotides range from 10 to 100 nucleotides, and are complementary for at least 50% to the specific amplification primers as above described. Decoys oligonucleotides are defined by a 3 overhang on one side and by a 5 blunt extremity on the other side. The difference between the melting temperature of each decoy oligonucleotide and the relative paired primer does not exceed 2 C.

[0131] Decoy oligonucleotides can be advantageous since they can prevent the amplification primers from aspecific interaction that create free 3 OH groups, accessible by polymerase, because their sequence is complementary to the amplification primers, their melting temperature is slightly lower and they do not create structures that expose free 3 OH groups.

[0132] According to embodiments, combinable with all embodiments described herein, PCR amplification can be for instance performed in a PCR thermocycler.

[0133] According to further embodiments, combinable with all embodiments described herein, PCR amplification can be typically performed in a real-time PCR machine, for instance a real-time PCR thermocycler.

[0134] Since, according to the present disclosure, the same sample is first subjected to the PCR amplification and then to HRM analysis, the whole method can be performed in a single apparatus, in particular a real-time PCR machine.

[0135] According to possible embodiments, the PCR amplification and detection can be performed simultaneously by means of Real Time PCR in any setup known in the art, including quantitative Real time PCR allowing assessment of the pathogenic load in the infected sample, followed by HRM analysis, performed in the same real-time PCR machine.

[0136] However, in other embodiments, the two operations, i.e. PCR amplification and HRM analysis, can also be performed in separate and distinct apparatuses coupled or associated each other, for instance a typical thermocycler for the PCR amplification and then a real-time PCR configured for HRM analysis.

[0137] For example, in possible implementations, the detection can be performed using a dedicated PCR device, also in portable format, containing a specific Peltier module coupled with a fluorescence optical reader or other appropriate reading device, able to perform HRM analysis.

[0138] In still further implementations, the detection via the PCR amplification can be performed using a dedicated PCR device containing for instance a specific Peltier module coupled to a read-out device different than a fluorescent read-out device, for instance a chemiluminescent or electrochemical read-out device, a conductimetric, amperometric, voltammetric read-out device, plasmonic optical red-out device or any other suitable read-out device.

[0139] Embodiments described herein can be used for diagnostic purposes. In particular, in the following, specific ranges of the reagents present in the two possible implementations of the PCR reaction mixture are described, that can be used for diagnostic purposes. Subsequently, specific ranges are described that can be used for specific detection of the HPV DNA.

[0140] In particular, the method and diagnostic kit containing the above-mentioned PCR reaction mixture according to the present disclosure can be used to detect clinical pathogens present in the sample, preferably blood borne pathogens including their genetic sequences.

[0141] In one embodiment, a possible first amplification buffer for diagnostic purposes comprises the dNTPs, the source of mono or bivalent cations, the buffer solution, the BSA, the Hot Start DNA polymerase, the intercalating molecule or compound. For instance, one specific implementation of the first amplification buffer comprises: [0142] a) dNTPs (final concentration range: from 0.05 mM to 0.3 mM) [0143] b) MgCl.sub.2 (final concentration range: from 0.3 mM to 4 mM) [0144] c) TrisHCl buffer solution (final concentration range: from 10 mM to 50 mM; pH from 6.00 to 10.00) [0145] d) KCl (final concentration range: from 10 mM to 50 mM) [0146] e) BSA (final concentration range: from 0.005 to 0.05 mg/ml) [0147] f) Hot Start polymerase [0148] g) SYTO-9 (final concentration range: from 1 M to 8 M).

[0149] In another possible embodiment, a possible alternative second amplification buffer for diagnostic purposes is provided, that comprises the dNTPs, the source of mono or bivalent cations, the buffer solution, BSA, the hot start DNA polymerase, the intercalating molecule or compound and the above mentioned additives. By the addition of additives, the second amplification buffer can be used as a PCR enhancer buffer providing increased diagnostic sensitivity, specificity and accuracy as above discussed. For instance, one specific implementation of the alternative second amplification buffer comprises: [0150] a) dNTPs (final concentration range: from 0.05 mM to 0.5 mM) [0151] b) MgCl.sub.2 (final concentration range: from 0.3 mM to 4 mM) [0152] c) TrisHCl buffer solution (final concentration range: from 10 mM to 50 mM; pH from 6.00 to 10.00) [0153] d) KCl (final concentration range: from 10 mM to 50 mM) [0154] e) BSA (final concentration range: from 0.005 to 0.05 mg/ml) [0155] f) Hot start polymerase [0156] g) SYTO-9 (final concentration range: from 1 M to 8 M) [0157] h) TMAC (Tetramethylammonium Cloride) (final concentration range: from 10 mM to 100 mM) [0158] i) Acetamide (final concentration range: from 0% to 5%) [0159] j) Formamide (final concentration range: from 0% to 5%) [0160] k) Betaine (final concentration range: from 0 M to 3 mM) [0161] l) Gelatine (final concentration range: from 0.01 mg/ml to 1 mg/ml).

[0162] In the embodiments of methods and diagnostic kit described herein for diagnostic purposes, since different PCR machine, i.e. different thermocycler models, may generate different curves and in particular different melting peaks, a calibrator is provided to set each real-time PCR machine for a correct and precise melting analysis required to genotype the pathogen. Indeed, some variations might occur due to machine type, efficiency due to maintenance status or acquisition settings, and the calibrator allows the adjustment of the observed measurements in a specific machine. The calibrator can be composed by synthetic oligonucleotides corresponding to the amplicons generated by the specific primers of the PCR reaction mixture according to the present disclosure. Advantageously, a machine-specific calibrator can be loaded in PCR runs periodically to check the effective melting temperature of the amplicons of a particular thermocycler machine, and compare it with the expected melting temperature.

[0163] Further embodiments described herein for diagnostic purposes provide primers for obtaining combinations of melting temperature, in order to increase the number of targets detectable in the same assays. The limit of the number of targets simultaneously detectable in a single well of a PCR machine is generally defined by the capability of the system to distinguish and resolve two proximal peaks. However, according to embodiments described herein, it is possible to increase the number of targets detectable in the same assays, providing two or more sets of primers that are specific for the same DNA targets. According to embodiments, a first set of primers is present in a PCR reaction mixture in one well, at least a second set is present in another well. Each set of primers comprises primers each recognizing one specific DNA target. The DNA targets recognized by the first set of primers are the same as the DNA targets recognized by the second set of primers and the melting temperature of an amplicon generated by a primer of one set of primers recognizing a specific DNA target is different from the melting temperature of an amplicon generated by a primer of the other set of primers recognizing said specific DNA target.

[0164] As indicated in the table below as an example, 3 targets are identified by two primer sets: Target #1 is recognized by set A and B, Target #2 is recognized by set C and D, Target #3 is recognized by set E and F. The PCR reaction mixture aliquoted in the well 1 contains primer sets A, C and E; the PCR reaction mixture aliquoted in the well 2 contains primer sets B, D and F.

TABLE-US-00001 Target Well 1 Well 2 Target#1 Primer set A Primer set B Target#2 Primer set C Primer set D Target#3 Primer set E Primer set F

[0165] For each target DNA, HRM data will be collected for each well; hence each target DNA will be defined not by one single melting peak, but for several melting peaks, one for each well, as indicated in the table below as an example:

TABLE-US-00002 Target T.sub.m well 1 T.sub.m well 2 Target#1 70 C. 71 C. Target#2 70 C. 82 C. Target#3 74 C. 70 C.

[0166] These embodiments allow the discrimination of more targets DNA thanks to the exponential increase in the number of possible combinations of the two or more melting temperatures that will be revealed, representing each of them a variable; thus, each target DNA will be precisely defined according multiple variables.

[0167] If x is the number of possible peaks distinguishable in a single well, the number of targets distinguishable in this embodiment is x.sup.a, where a is the number of sets of primers used for each target, and consequently the number of wells used for each sample.

[0168] This variant is particularly useful when the application aims at differentiating high number different targets (such as it occurs in HPV genotyping, where 40 genotypes can be simultaneously analysed and defined by the embodiments according to the present disclosure).

[0169] In the following, embodiments of methods and diagnostic kit according to the present disclosure are described for specific use for HPV diagnosis, using specific primers. In one embodiment, methods and diagnostic kit of the present disclosure are used to detect Human Papillomavirus DNA in clinical samples and to discriminate different genotypes by HRM analysis.

[0170] According to one embodiment, the methods and diagnostic kit, in addition to any of the afore-described combination of reagents required for carrying out DNA amplification by PCR, includes specific primers for each genotype of HPV are included from SEQ ID No. 20 to SEQ ID No. 616 and from SEQ ID No. 655 to SEQ ID No. 706 provided in the sequence listing attached hereto. The afore-mentioned specific primers for HPV diagnosis are characterized by the following features: [0171] 1) difference in melting temperature of different primers does not exceed 30 C. [0172] 2) primers amplify HPV genotypes producing amplicons from 40 to 1500 bps. [0173] 3) primers amplify an amplicon wherein the melting peak of the amplicon is between 68 and 95 C. [0174] 4) each primer is present in the PCR reaction mixture at a final concentration range from 50 to 1000 nM.

[0175] In yet further embodiments, one further set of normalizing primers can be provided, for the amplification of human genomic DNA, said amplification of human genomic DNA serving as an internal PCR validation control and/or control for normalization of the amplified pathogen, e.g. HPV, DNA obtained according to any of the embodiments described herein. An example of such pair of normalizing primers targeting a fragment from the human beta-globin gene is provided in SEQ ID No. 630 and SEQ ID No. 631 of the sequence listing attached hereto.

[0176] In a preferred embodiment of the diagnostic kit for HPV diagnosis, specific primers for the 13 most frequent high risk HPV serotypes are provided in the PCR reaction mixture of the present disclosure, that have the sequences SEQ ID NO. 591 to SEQ ID No. 616 of the sequence listing attached hereto.

[0177] In one embodiment, a specific amplification buffer for HPV diagnosis comprises the following reagents with concentration expressed as ranges: [0178] a) dNTPs (final concentration range: from 0.05 mM to 0.5 mM) [0179] b) MgCl.sub.2 (final concentration range: from 0.3 mM to 4 mM) [0180] c) TrisHCl buffer solution (final concentration range: from 10 mM to 50 mM; pH from 7.00 to 10.00) [0181] d) KCl (final concentration range: from 10 mM to 50 mM) [0182] e) BSA (final concentration range: from 0.005 mg/ml to 0.05 mg/ml) [0183] f) Hot start polymerase [0184] g) SYTO-9 (final concentration range: from 1 M to 8 M).

[0185] One example of possible specific concentration values of the reagents is the following: [0186] a) dNTPs (final concentration 0.2 mM) [0187] b) MgCl.sub.2 (final concentration 0.75 mM) [0188] c) TrisHCl buffer solution (final concentration 30 mM: and pH 9.0) [0189] d) KCl (final concentration 50 mM) [0190] e) BSA (final concentration 10 g/ml) [0191] f) Hot Start polymerase [0192] g) SYTO-9 (final concentration 4 M).

[0193] In another possible embodiment, a further alternative possible specific amplification buffer for HPV diagnosis, providing increased diagnostic sensitivity, specificity and accuracy comprises the following reagents with concentration expressed as ranges: [0194] a) dNTPs (final concentration range: from 0.05 mM to 0.3 mM) [0195] b) MgCl.sub.2 (final concentration range: from 0.3 mM to 4 mM) [0196] c) TrisHCl buffer solution (final concentration range: from 10 mM to 50 mM; pH from 7.00 to 10.00) [0197] d) KCl (final concentration range: from 10 mM to 50 mM) [0198] e) BSA (final concentration range: from 0.005 mg/ml to 0.05 mg/ml) [0199] f) Hot start polymerase [0200] g) SYTO-9 (final concentration range: from 1 M to 8 M) [0201] h) TMAC (Tetramethylammonium Cloride) (final concentration range: from 10 mM to 100 mM) [0202] i) Acetamide (final concentration range: from 0.5% to 5%) [0203] j) Formamide (final concentration range: from 0.5% to 5%) [0204] k) Betaine (final concentration range: from 100 M to 3 mM) [0205] l) Gelatine (final concentration range: from 0.01 mg/ml to 1 mg/ml).

[0206] One example of possible specific concentration values of the reagents of this further alternative amplification buffer is the following: [0207] a) dNTPs (final concentration 0.15 mM) [0208] b) MgCl.sub.2 (final concentration 0.75 mM) [0209] c) TrisHCl buffer solution (final concentration 30 mM; pH 9) [0210] d) KCl (final concentration: 40 mM) [0211] e) BSA (final concentration 10 g/ml) [0212] f) Hot start polymerase [0213] g) SYTO-9 (final concentration 2 M) [0214] h) TMAC (Tetramethylammonium Cloride, final concentration of 75 mM) [0215] i) Acetamide (final concentration 3%) [0216] j) Formamide (final concentration 1.5%) [0217] k) Betaine (final concentration 0.5M) [0218] l) Gelatine (final concentration 0.1 mg/mL).

[0219] Advantageously, the diagnostic HPV test based on the embodiments described herein can provide at least two important information about HPV testing and screening: [0220] 1) a diagnostic information: the amplification curves obtained by the PCR allow the detection of the first 14 high risk genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68Cit. IARC 2009) and thus give a diagnostic information. A sample is positive when the amplification curve occurs before 35 PCR cycles using a fluorescence threshold that range from 250.000 to 400.000. The present invention has been tested on positive samples (extracted DNA of 150 women with a CIN2+ cytology, according with Mejer guide lines, 2009). Clinical data showed that sensitivity of the diagnostic HPV test according to the embodiments described herein, intended as the sensitivity to detect High-Grade Squamous Intraepithelial Lesions (HSIL or CIN2/3 lesions, that are considered the clinical endpoint in the HPV diagnostics), is 98%. Sensitivity is the percentage of HPV-infected people with a diagnosed HSIL that are detected by the HPV test according to the embodiments described herein, divided by the total number of HPV-infected people with a diagnosed HSIL detected by conventional test (e.g. Pap test). The test specificity reaches almost the 100% and the test accuracy ranges from 0.93 to 0.98; [0221] 2) the melting fingerprinting analysis obtained by the HRM analysis allows the genotyping of all the above-mentioned 14 high risk HPV genotypes. Indeed, the HPV vaccine administration is changing the HPV genotypes prevalence among different populations, and some High Risk HPVs, once very rare, are becoming more frequent. Besides that, this information is also important in later, possible triage steps because different HPV genotypes have different capabilities to induce cancer development. Genotyping is also able to distinguish between transient infections, that are very common and spontaneously resolved, and persistent infection of a certain high risk HPV type, that can eventually lead to cancer.

[0222] According to still further embodiments, combinable with all embodiments described herein, methods and diagnostic kit according to the present disclosure can be used to detect and discriminate further different pathogens responsible for other sexually transmitted diseases, such as chlamydia infection, syphilis infection, or gonorrhoea infection, by using specific amplification primers according to SEQ ID No. 1 to SEQ ID No. 19 and from SEQ ID No. 636 to SEQ ID No. 654 of the sequence listing attached hereto in the PCR reaction mixture as above described.

[0223] While the foregoing is directed to embodiments of the invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow.

BIBLIOGRAPHY

[0224] 1. Munoz et al. HPV and the ethiology of human cancer. Vaccine (2006). [0225] 2. Herrero et al. Human Papillomavirus and oral cancer: The International Agency for Research on Cancer multicentre study. J Natl Cancer (2003). [0226] 3. de Villiers et al., Classification of Papillomavirus. Virology (2004). [0227] 4. Munoz et al., Epidemiologic classification of Human Papillomavirus Types associated with cervical cancer. N Engl J Med (2003). [0228] 5. Cuzick et al., Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006). [0229] 6. Clavel et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer (2001). [0230] 7. Ronco et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol. (2010). [0231] 8. Arbyn et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012). [0232] 9. Dillner et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008). [0233] 10. Sderlund-Strand et al. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol (2011). [0234] 11. Naucler et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br. J. Cancer (2007). [0235] 12. Pierce Campbell et al. Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prey Res (Phila) (2015). [0236] 13. Don et al. Incidence, clearance and duration of cutaneous beta and gamma human papillomavirus anal infection. J Infect Oct (2016). [0237] 14. Dillner et al. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. (2007). [0238] 15. Poljak et al. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Vir (2015).